WYC-209 is a novel inhibitor of tumor-repopulating cells (trcs), inducing trc apoptosis primarily via the caspase 3 pathway. WYC-209 induces apoptosis primarily via the caspase 3 pathway with IC50 of 0.19 μM for inmalignant murine melanoma TRCs.
In vivo, WYC-209 (0.022-0.22 mg/kg; i.v.; once every two days for 25 days) inhibits tumor metastasis in C57BL/6 mice bearing lung metastases.
Cell Experiment | |
---|---|
Cell lines | A2780, A549, MCF-7, MDA-MB-435s, A375 cells |
Preparation method | Human ovarian cancer A2780 (a), human lung cancer A549 (b), human breast cancer MCF-7 (c), human melanoma MDA-MB-435s (d), and human malignant melanoma A375 (e) were cultured in 90-Pa fibrin gels for 3 days and treated with 0.1, 1, or 10 μM WYC-209. f–j A2780, A549, MCF-7, MDA-MB-435s, and A375 were cultured in 90-Pa fibrin gels for 3 days, treated with 10 μM WYC-209, and were then washed out of the compound on day 4. |
Concentrations | 10 μM |
Incubation time | 24 hours |
Animal Experiment | |
---|---|
Animal models | Female immune-competent C57BL/6 mice |
Formulation | 0.1% DMSO |
Dosages | 0.022, 0.22 mg/kg |
Administration | intravenously injected; once every two days for 25 days |
Molecular Weight | 368.45 |
Formula | C20H20N2O3S |
CAS Number | 2131803-90-0 |
Solubility (25°C) | DMSO 70 mg/mL |
Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
Related RAR/RXR Products |
---|
MSU-42011
MSU-42011 is an orally active retinoid X receptor-like (RXR) agonist that potently inhibits the expression of iNOS as well as p-ERK protein levels. In addition, MSU-42011 has immunomodulatory and antitumor activities for cancer research. |
KCL-286
KCL-286 is an orally active retinoic acid receptor-beta (RAR-beta) agonist for studies related to spinal cord injury. |
XS-060
XS-060 is a potent anticancer agent and RXRα antagonist. |
BPA-B9
BPA-B9 is a RXRα ligand and antagonist targeting the pRXRα-PLK1 interaction. |
ER 50891 quarterhydrate
ER 50891 quarterhydrate is a potent antagonist of retinoic acid receptor α(RARα). |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.